Alpha memo: prostate cancer selenium vitamin endpoint split

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Rename and reframe the memo to reflect the actual evidence bundle: a cross-trial, cross-organ signal comparison between SELECT prostate cancer risk (obesity association) and SELECT colorectal adenoma outcomes (selenium/vitamin E).
2. Rewrite the one-sentence alpha to clearly state the bounded cross-trial contrast: e.g., 'Receipt 1 examines obesity–prostate cancer risk association in SELECT; Receipt 2 examines selenium/vitamin E effects on colorectal adenoma occurrence in SELECT; the memo contrasts these two endpoint families within the same trial platform.'
3. Remove or repair the broken prose in the abstract and sections to ensure clarity and coherence.
4. Clarify the falsifier: the memo should state that the cross-organ endpoint contrast is exploratory and not a direct replication; falsification would require measuring both endpoints in the same population.

Major issues

• Title/source alignment failure: The title and abstract claim a 'prostate cancer selenium vitamin endpoint split' but the evidence bundle contains one prostate cancer receipt (obesity association) and one colorectal adenoma receipt (selenium/vitamin E trial). These are not comparable endpoints for a bounded contrast; they are from different organ systems and trial designs.
• The memo’s 'one-sentence alpha' is grammatically and semantically broken, obscuring the intended claim and violating clarity.
• The memo claims a 'bounded population/endpoint split' but does not justify comparing prostate cancer risk (Receipt 1) with colorectal adenoma occurrence (Receipt 2) as a coherent signal; these are not the same endpoint family.

Minor issues

• The abstract and sections contain redundant, poorly edited prose (e.g., 'reducing obesity among.; Receipt 2 reports...').
• The 'Why this is surprising' section repeats findings without adding synthesis or integration.

Reviewer note

The memo fails title/source alignment and presents a non-comparable endpoint contrast. The evidence bundle does not support the claimed 'bounded population/endpoint split' because the endpoints (prostate cancer risk vs. colorectal adenoma occurrence) are from different organ systems and trial objectives. The memo’s prose is also broken and unclear, compounding the structural flaw. A rename and reframe to an explicit cross-trial, cross-organ comparison within SELECT could salvage the memo, but as currently written it is structurally broken and must be rejected.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak

Prompt: reviewer-v11-research-synthesis